Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab-Reference-Cited by-同舟云学术

Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab

Published:2020-09-04 Issue:4 Volume:112 Page:597-598
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Tomuleasa Ciprian^ORCID,Iluta Sabina,Pasca Sergiu,Roman Andrei,Piciu Doina,Jitaru Ciprian,Teodorescu Patric,Rus Ioana,Bojan Anca,Dima Delia,Zdrenghea Mihnea,Petrushev Bobe

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-020-02989-5.pdf

Reference5 articles.

1. Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, et al. Analysis of Japanese Patients From the AUGMENT Phase III Study of Lenalidomide + Rituximab (R2) vs. Rituximab + Placebo in relapsed/refractory Indolent non-Hodgkin Lymphoma. Int J Hematol. 2020;111(3):409–16.

2. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–16.

3. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

4. Zinzani PL, Pellegrini C, Argnani L, Broccoli A. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 2016;101(9):e385–e386386.

5. Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas R-O, Fruchart C, Morschhauser F, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–81.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial;Cancers;2021-09-15